NASDAQ:IRLA

Quince Therapeutics Q3 2026 Earnings Results & Report

Quince Therapeutics logo
$40.07 -0.52 (-1.28%)
As of 02:46 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Quince Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$2.31 versus the -$0.84 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

Quince Therapeutics EPS Results

Actual EPS
-$2.31
Consensus EPS
-$0.84
Beat/Miss
Missed by -$1.47
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 7 quarters

Quince Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quince Therapeutics Q3 2026 Earnings FAQ

Quince Therapeutics (NASDAQ:IRLA) reported earnings of -$2.31 per share for Q3 2026, missing the consensus estimate of -$0.84. The report was announced on Friday, November 13, 2026.

Quince Therapeutics Earnings Headlines

Don’t delete this, read it today
Porter Stansberry has spent more than 30 years studying the economy and financial markets, and says he has never felt pressure like this. He believes the foundations beneath our way of life have cracked. One Nobel Prize winner has warned that the force behind it threatens to divide America. Stansberry points to rising living costs, deepening division and building anger as signs. His documentary, The Final Displacement, names the force and outlines what he believes you can do about it now.tc pixel
See More Quince Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quince Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quince Therapeutics and other key companies, straight to your email.

About Quince Therapeutics

Quince Therapeutics (NASDAQ:IRLA) is a clinical-stage biotechnology company developing therapies for rare diseases and other conditions with significant unmet medical needs. The company’s technology platform is designed to use patients’ own red blood cells to deliver therapeutic compounds, with the goal of providing sustained treatment while limiting systemic exposure.

Quince’s lead program is the EryDex System, an investigational treatment that loads dexamethasone sodium phosphate into a patient’s red blood cells for controlled release. The program has been evaluated for ataxia-telangiectasia, a rare inherited disorder affecting neurological, immune and other bodily systems. As an investigational therapy, the EryDex System remains subject to clinical testing and regulatory review.

The company’s operations and clinical development activities have involved the United States and Europe. Quince was formed through a combination with EryDel, the developer of the EryDex technology, and has continued advancing the program through clinical development. Information about additional pipeline programs and current leadership may change as the company’s development strategy evolves.

View Quince Therapeutics Profile